Effectiveness of atorvastatin in acute atherothrombotic cerebral infarction

Introduction: Cerebrovascular Diseases (CVD) constitute one of the most important health problems on a global scale and in Cuba they occupy the third cause of death and the first cause of disability. Objective: To evaluate the use of atorvastatin in the acute phase of atherothrombotic cerebral infarction. Method: A prospective longitudinal study was carried out in patients who attended the on-call department of the Julio Trigo López Hospital and were diagnosed with acute atherothrombotic cerebral infarction, who were randomly administered with prior informed consent: 0, 20 mg or 40 mg of atorvastatin , they underwent CAT (Computerized Axial Tomography) of the skull, which was repeated on the third day and at 30 days, the value of PCR (C Reactive Protein) was determined in on-call body, on the fifth day and at 30 days, they were clinically evaluated according to the NIHSS scale (National Institute of Health Stroke Scale) in on-call body , daily during their admission and 30 days later. Results: The size of the infarct area decreased by 19.4% with 40 mg of atorvastatin as did the CRP value which was reduced by 16 mg/Ll. The clinical assessment (NIHSS scale) was reduced according to the dose of atorvastatin by slightly more than 8 points. Conclusions: The decrease in infarct area was directly proportional to the dose of atorvastatin used, just as the CRP values were lower and the favorable clinical evolution was associated with the use of this.